SAVA240920C28000
- 1.73
- 0.000.00%
Cassava Sciences Newsroom
Cassava Sciences Analyst Ratings
H.C. Wainwright Maintains Cassava Sciences(SAVA.US) With Hold Rating
JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)
Cassava Sciences Analyst Ratings
Cassava Sciences Analyst Ratings
H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)
Cassava Sciences Analyst Ratings
Cassava Sciences (SAVA) Was Downgraded to a Hold Rating at H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Aroa Biosurgery Ltd (AU:ARX), Cassava Sciences (SAVA) and Amplifon S.p.A. (GB:0N61)
Cassava Sciences Analyst Ratings
Cassava Sciences Progresses in Phase 3 Trials, Secures Strong Cash Position: A Buy Rating Justified
Cassava Sciences Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX)
Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), CymaBay Therapeutics (CBAY)
Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)
Cassava Sciences' Simufilam Efficacy and Safety in Alzheimer's Treatment Bolsters Buy Rating: An Analysis of Trial Results and Future Projections
Positive Phase 3 Trials and Undervalued Stock: Buy Rating Suggested for Cassava Sciences
Buy Rating for Cassava Sciences: Rapid Alzheimer's Trials Progress and Strong Financial Health
Cassava Sciences (SAVA) Gets a Buy From JonesTrading
HC Wainwright & Co. Reiterates Buy on Cassava Sciences, Maintains $124 Price Target